Please login to the form below

PD-L1 inhibitors

This page shows the latest PD-L1 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Soon-Shiong presents first data on cancer memory vaccine at SITC

Its ‘memory cancer vaccine’consists of a cocktail of off-the-shelf NK cells delivered alongside low-dose chemotherapy, cytokines, yeast- and adenovirus-delivered tumour antigens and PD-1/PD-L1 ... checkpoint inhibitors – all designed to stimulate a

Latest news

Merck’s Bavencio joins first-line kidney cancer face-off

Taken together, while checkpoint inhibitors are now the standard of care in frontline RCC, PD-L1-positive patients tend to derive the most benefit, ”notes Hsieh. ... In our view, combination with TKI could expand the clinical benefit of checkpoint
China’s BeiGene takes PD-1 antibody into pivotal trials

The PD-1/PD-L1 category has been transforming cancer treatment in Western markets, but so far just one of the five approved drugs have been launched in the big Chinese ... There is a huge pent-up need for new cancer immunotherapies. However, while the
Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

Armo has said it thinks that the drug will increase the activity of PD-1/PD-L1 checkpoint inhibitors. ... Lilly already has a PD-L1 drug in phase I testing, while Armo also has a PD-1 antibody heading for clinical trials as well as recombinant IL-12 and
BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

Meanwhile another study of epacadostat with AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will also not go ahead. ... 1/PD-L1 inhibitors, but the drug has been firmly relegated to speculative status.
Merck’s Keytruda scores in frontline lung cancer yet again

NSCLC, including those with both squamous and non-squamous types and a full range of PD-L1 expression levels from 1% and above. ... are both hoping to find a role for combinations pairing PD-1/PD-L1 inhibitors with CTLA4 inhibitors.

More from news
Approximately 1 fully matching, plus 30 partially matching documents found.

Latest Intelligence

The good, the bad and the ugly

Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response, ”says Xuan.
European venture funding for the life science sector

is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture
Medius Deal Watch table for March 2015

170. Checkpoint Therapeutics / TG. Licence and collaboration. Human anti-PD-L1 and anti-GITR antibody preclinical programmes for haematological cancers. ... CAR-T and checkpoint inhibitors PD-1 and PD-L1. 110. Transtech / Calithera.
Deal Watch table for November 2014

PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Editorial Manager - MedComms: DOE

Business Director: Competitive Salary Offered

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Principal Health Economist - North-West: Negotiable

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Executive/ Senior Account Executive: competitive Salary Offfered

Account Manager / Account Director: Competative

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Healthcare Communications Account Directors x 2: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Director: Competitive Salary Offered

Business Development Director – Health Education: excellent commission

Medical (Scientific) Director: £120, 000 benefits

Experienced Medical Writers: Competitive Salary and Benefits

Senior Account Manager: Competitive Salary Offered

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Associate Director: £75, 000-90, 000

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Account Manager- Healthcare Advertising: Negotiable

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?: What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma: Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies: Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...